---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-049756"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T02:47:56.072521+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sagimet Biosciences prices public offering of 29.2M shares at $6.00/share for ~$164.5M net proceeds

## Summary
- Offering of 29,166,700 shares of common stock at $6.00 per share; net proceeds expected $164.5 million.
- Net proceeds to fund Phase 3 trial of denifanstat in acne, TVB-3567 through Phase 2, and topical FASN inhibitor to IND.
- Joint book-running managers: Leerink Partners, TD Securities, Guggenheim Securities, and Oppenheimer & Co.
- Co-lead managers: Canaccord Genuity, H.C. Wainwright, and JonesTrading.

## SEC filing metadata
- accession: 0001104659-26-049756
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465926049756/0001104659-26-049756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465926049756/tm2612794d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-049756
- JSON: https://secwatch.observer/filing/0001104659-26-049756.json
- Plain text: https://secwatch.observer/filing/0001104659-26-049756.txt

## Source-grounded claims
- claim_id: d50b03ef5bba22def012590d840a2954ae9e16e2
  claim: Sagimet Biosciences Inc. entered into Underwriting Agreement with Leerink Partners LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC as representatives of the several underwriters valued at $164.5 million (effective 2026-04-27).
  evidence_excerpt: On April 27, 2026, Sagimet Biosciences Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC as representatives of the several underwriters named therein (the “ Underwriters ”) relating to an underwritten offering (the “ Offering ”) of 29,166,700 shares (the “ Shares ”) of the Company’s Series A common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $6.00 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1400118/000110465926049756/0001104659-26-049756-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.